Copyright
©The Author(s) 2019.
World J Hepatol. Jun 27, 2019; 11(6): 531-541
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.531
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.531
Rifaximin (n = 38) | Control (n = 38) | P value | |
Age (yr) | 69 (40-85) | 69.5 (42-90) | 0.934 |
Sex (female/male) | 17 (44.7%)/21 (55.3%) | 11 (28.9%)/27 (71.1%) | 0.234 |
BMI (kg/m2) | 24.78(18.67-35.88) | 23.1 (15.5-30.1) | 0.035 |
Etiology (HBV/HCV/Alcohol/NASH) | 7 (18.4%)/5 (13.2%)/13 (34.2%)/5 (13.2%) | 4 (10.5%)/14 (36.8%)/9 (23.7%)/3 (7.9%) | 0.107 |
Child-Pugh A/B/C | 15 (39.5%)/15 (39.5%)/8 (21.1%) | 20 (52.6%)/ 17 (44.7%)/1 (2.6%) | 0.051 |
ALBI Grade | 1(2.6%) /27 (71.1%) /10 (26.3%) | 22 (57.9%)/15 (39.5%)/1(2.6%) | < 0.001 |
MELD Score1 | 6 (2-17) | 9 (0-22) | 0.205 |
ALT (IU/L)1 | 24.5 (8.0-105.0) | 31.5 (8.0-1490) | 0.109 |
AST (IU/L)1 | 39.5 (20.0-136.0) | 45 (15-1041) | 0.426 |
GGTP (IU/L)1 | 35.5 (11.0-558.0) | 64 (14-506) | 0.055 |
Serum ammonia | 104 (59-297) | 52 (23-89) | < 0.001 |
Albumin (g/dL)1 | 3.0 (2.1-4.4) | 4.05 (2.4-5.0) | < 0.001 |
Total bilirubin (mg/dL)1 | 1.65 (0.4-4.7) | 1.0 (0.4-8.6) | 0.002 |
Platelet count (×103/μL)1 | 8.7 (4.8-27.9) | 12.3 (2.3-30.2) | 0.023 |
Prothrombin activity (%) | 60 (38-133) | 69 (14-108) | 0.066 |
AFP (ng/mL)1 | 4.3 (1.0-3375) | 6.25 (1.3-385.5) | 0.065 |
DCP (mAU/mL)1 | 37 (15-3178) | 25 (11-11688) | 0.383 |
Fibrosis 4 index1 | 5.61 (1.71-15.1) | 4.25 (1.2-33.4) | 0.117 |
MRE (kPa)1 | 5.04 (3.00-11.11) | 4.86 (3.36-12.50) | 0.748 |
SWE (kPa)1 | 23.1 (8.3-56) | 16.8 (7.0-36.8) | < 0.001 |
History of overt hepatic encephalopathy | 12 (31.6%) | 0 (0%) | < 0.001 |
HCC | 9 (23.7%) | 12 (31.6%) | 0.442 |
Ascites | 11 (29.0%) | 10 (26.3%) | 0.834 |
Esophageal varices | 27 (71.1%) | 23 (60.5%) | 0.469 |
Max diameter of portosystemic shunts (mm) | 7.6 (1.7-18.5) | 4.2 (1.6-10.9) | < 0.001 |
Number of portosystemic shunts (0,1/2-) | 8 (22.2%)/28 (77.8%) | 24 (63.2%)/14 (36.8%) | 0.001 |
Lactulose | 29 (76.3%) | 6 (15.8%) | < 0.001 |
BCAA | 24 (63.2%) | 14 (36.8%) | 0.038 |
Sarcopenia | 17 (44.7%) | 17 (44.7%) | 1 |
Follow up period (wk)1 | 61 (24-91) | 91 (5-120) | < 0.001 |
Category | HR (95%CI) | P value |
Univariate analysis | ||
Age (yr at MRE) | ||
< 70 | 1 | |
≥ 70 | 2.2 (0.56-8.7) | 0.26 |
Sex | ||
female | 1 | |
male | 0.491 (0.128-1.88) | 0.30 |
BMI (kg/m2) | ||
< 28 | 1 | |
≥ 28 | 0.42 (0.094-1.85) | 0.25 |
AST (IU/L) | ||
< 36 | 1 | |
≥ 36 | 0.372 (0.094-1.47) | 0.16 |
ALT (IU/L) | ||
< 30 | 1 | |
≥ 30 | 0.43 (0.11-1.7) | 0.23 |
GGTP (IU/L)a | ||
< 42 | 1 | |
≥ 42 | 0.71 (0.18-2.87) | 0.64 |
Albumin (g/dL) | ||
≥ 3.0 | 1 | |
< 3.0 | 3.3 (0.83-13) | 0.091 |
Total bilirubin (mg/dL) | ||
< 1.4 | 1 | |
≥ 1.4 | 3.0 (0.76-12) | 0.12 |
Platelet count (×103/μL) | ||
≥ 6.8 | 1 | |
< 6.8 | 4.1 (0.67-25) | 0.13 |
Prothrombin activity (%) | ||
< 58 | 1 | 0.13 |
≥ 58 | 3.0 (0.72-13) | |
AFP (ng/mL) | ||
< 6.5 | 1 | |
≥ 6.5 | 3.25 (0.55-19) | 0.20 |
DCP (mAU/mL) | ||
< 18 | 1 | |
≥ 18 | 3.6 (0.57-23) | 0.17 |
Ascites | ||
Absent | 1 | 0.16 |
Present | 2.5 (0.70-8.8) | |
Esophageal varices | ||
Absent | 1 | 0.42 |
Present | 1.8 (0.43-7.5) | |
History of hepatic encephalopathy | ||
Absent | 1 | 0.11 |
Present | 3.6 (0.77-16) | |
HCC1 | ||
Absent | 1 | 0.72 |
Present | 0.75 (0.16-3.6) | |
Sarcopenia | ||
Absent | 1 | 0.49 |
Present | 1.64 (0.41-6.6) | |
Child-Pugh Score | 0.061 | |
< 7 | 1 | |
≥ 7 | 3.9 (0.94-16) | |
ALBI Score | ||
< -1.6 | 1 | |
≥ -1.6 | 5.3 (1.1-25) | 0.033 |
MELD Score | ||
< 12 | 1 | 0.13 |
≥ 12 | 3.0 (0.72-13) | |
Fibrosis 4 index | ||
< 8.3 | 1 | |
≥ 8.3 | 0.42 (0.094-1.9) | 0.25 |
MRE (kPa) | ||
< 5.0 | 1 | 0.43 |
≥ 5.0 | 1.63 (0.40-8.3) | |
SWE (kPa) | ||
< 17.7 | 1 | |
≥ 17.7 | 3.0 (0.65-14) | 0.16 |
Max diameter of portosystemic shunt | ||
< 8.0 | 1 | |
≥ 8.0 | 6.8 (1.4-33) | 0.017 |
Number of portosystemic shunt systems | ||
0,1 | 1 | 0.68 |
2-4 | 1.36 (0.32-5.9) | |
Multivariate analysis | ||
Max diameter of portosystemic shunt | ||
< 8.0 | 1 | |
≥ 8.0 | 5.5 (1.1-28) | 0.039 |
ALBI Score | 0.16 | |
< -1.6 | 1 | |
≥ -1.6 | 3.3 (0.62-18) |
- Citation: Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541
- URL: https://www.wjgnet.com/1948-5182/full/v11/i6/531.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i6.531